Neboglamine

Neboglamine ( ) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of…

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Neboglamine ( ) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence. It shows cognition- and memory-enhancing effects in animal models. As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083189 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001377083189 · captured 2026-09-27 · ledger · version history

Cite this page as: encyclopegia.org, “Neboglamine”, snapshot enwiki-001377083189. https://encyclopegia.org/a/neboglamine

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.